Operator

Greetings. Welcome to the Medexus Pharmaceuticals fiscal fourth quarter and year end 2026 conference call. [Operator Instructions] Please note, this conference is being recorded. I will now like to turn the conference over to your host Victoria Rutherford, Investor Relations of Medexus. You may begin.

Victoria Rutherford
Adelaide Capital

Thank you and good morning, everyone. Welcome to the Medexus Pharmaceuticals fiscal fourth quarter and year end 2026 earnings call. On the call this morning are Kenneth d'Entremont, Chief Executive Officer, and Brendon Buschman, Chief Financial Officer. If you have any questions after the conference call or would like further information about the company, please contact Adelaide Capital at (480) 625-5772. I would like to remind everyone that this discussion will include forward-looking information as defined in Canadian Securities Laws that is based on certain assumptions that Medexus believes to be reasonable in the circumstances, but is subject to risks and uncertainties. Actual results may differ materially from historical results or results anticipated by the forward-looking information.

In addition, this discussion will also include non-GAAP measures, such as adjusted EBITDA, adjusted EBITDA margin, and adjusted gross margin and net debt, which do not have any standardized meaning under IFRS, and therefore may not be comparable to similar measures presented by other companies. For more information about forward-looking information and non-GAAP measures, including reconciliations, please refer to the Company's MD&A, which along with the financial statements, is available on the company website at www.medexus.com and on SEDAR+ at www.sedarplus.ca. As a reminder, Medexus reports on